Connect with us

Psilocybin

This Undervalued Stock is Developing Biotechnology-Enhanced Therapeutics to Treat Mental Health.

A therapeutics biotech firm targeting the rapidly evolving mental health space.
The post This undervalued stock is developing biotechnology-enhanced therapeutics…

Published

on

Hot biotech stock! Discover how Cybin is revolutionizing mental health care

CYBIN NEO:CYBN | AMEX:CYBN

Cybin is a therapeutics biotech firm targeting the rapidly evolving mental health space in the North American market. This presents an exciting opportunity for investors to get in early.

  • Cybin has accumulated a library of over 50 molecules.
  • It is creating second-generation therapeutics using biotechnology.
  • Improving drug delivery through inhalation, orally disintegrating tablets, and sublingual film.
  • Reforming dose and duration.
  • Cybin has raised over $120M and is well-funded to progress its clinical trials, M&A, and IP strategies.
  • Cybin is undervalued in comparison to its billion-dollar competitors Compass Pathways and MindMed.

Using a scaffolding approach

Cybin’s ultimate goal is to progress psychedelic therapeutics with the power of biotechnology. The company is enhancing the best mind-expanding compounds to quantify the ideal dose and perfect trip time.

To do this, Cybin is using a molecular scaffolding approach.

It intends to build hybrid therapeutics with optimum capabilities. This will distribute desperately-needed treatments to a wider reach of society.

Meanwhile, it plans to improve the delivery process and lay crucial groundwork for the next generation of mental health treatments.

Doug Drysdale, Cybin CEO, noted:

“WE ARE FOCUSED ON ADDRESSING THE MENTAL HEALTH CRISIS AND TRANSFORMING THE TREATMENT LANDSCAPE. TO DO THAT, WE ARE COMBINING TECHNOLOGY AND OUR SCIENTIFIC EXPERTISE TO PAIR NOVEL PSYCHEDELIC MOLECULES WITH CONTROLLABLE DRUG DELIVERY SYSTEMS, AIMED AT IMPROVING OUTCOMES FOR PATIENTS.“

Over the past five years, Cybin has accumulated a library of over 50 molecules. These are based on the much-coveted mind-enhancing properties of DMT, MDMA, Psilocybin, and other related composites.

Improving intensity and duration

Classic hallucinogens have proven powerful potential, but they face some pitfalls: their intensity and duration.

Some psychedelic effects last just a few minutes but are wildly intense, causing physical side effects. Others are gentler, take a long time to kick in but hours to wear off.

To have a useful place in society as a viable therapeutic, determining duration and intensity will be a gamechanger.

Here’s where Cybin is making inroads. It enhances the original psychedelic tryptamines (the metabolites that regulate the dopamine and serotonin receptors) to extend or shorten their lives.

With over 700m people suffering from mental health disorders globally today, a solution is desperately needed, and Cybin can help.

This is an opportunity the savvy investor will not want to miss.

CLICK HERE to READ the Cybin investor deck for an inside look at this lucrative opportunity.

Transforming delivery and formulation

Cybin has several projects in development. In addition to its drug discovery platform, it is researching and developing drug delivery and formulation approaches.

Cybin is innovating the delivery method via inhalation, orally disintegrating tablets (ODTs), and sublingual film.

Inhalation can be a fast-acting way to administer the drug while giving the participant control over treatment intensity.

Cybin’s ODT uses a freeze-drying process that has seamless compatibility with the company’s secret molecule (patent pending).

But Cybin’s main project to date is designing a sublingual film of psilocybin to be administered under the tongue. This allows the drug to enter the bloodstream rapidly, bypassing the GI tract and liver, where oral administration loses potency.

This CYB001 compound has already achieved approval for a Phase II study in major depressive disorders.

Meanwhile, the company is advancing towards a Phase I study for resistant psychiatric disorders. And its anxiety and alcohol use disorder programs are in late-stage preclinical studies.

Furthermore, Cybin is powering the development of a software-based platform to support patient therapies. By collecting vital data from neuroimaging and analytics through machine learning, the company intends to arm clinicians with the necessary data to improve patient outcomes.

Recurring revenue potential

Cybin’s alcohol use disorder program should also be of particular interest to potential investors.

Sadly, alcohol is a silent killer and the third largest preventable cause of death globally. Therefore, there is a massive addressable market crying out for treatment options that are largely unmet.

Cybin’s solution could potentially eliminate the patient’s craving and dependency for a set period of time. This would be a gamechanger in the battle against addiction. It could lead to recurring revenue for Cybin, and major relief to the destruction alcoholism causes in families and society at large.

Once proven, this therapeutic could be replicated to treat other addictions, such as the mounting opioid crisis and more.

The prominence of recurring revenue will stem from the frequency of treatments. Part of Cybin’s research is to uncover the optimum strength and duration of treatment in relation to the extent of relief it provides.

For instance, does a 6-hour trip lead to a year of contentment and a 2-hour trip only 2 months? Or will the 2-hour treatment still provide the participant with 12 months in recovery?

Cybin aims to find out.

The goal is to assist as many sufferers as possible. In our time-starved society, shorter treatment times may be more appealing. Consequently, the increased frequency of treatments would lead to recurring revenue streams.

This is just one of the compelling reasons investors are eager to buy shares in Cybin.

Enhancing the path to profitability

CYBIN NEO:CYBN | AMEX:CYBN

Cybin is taking a parallel path to profitability by channeling its focus on more than one revenue stream.

Along with treatment regimens for psychiatric disorders and advancing its portfolio of next-generation therapeutics, Cybin is in partnership with ground-breaking mind-mapping company Kernel.

Kernel is developing a miniaturized a mind-reading helmet to aid in researching brain destruction caused by concussion, aging, psychedelic excursions, stroke, and meditations.

Kernel is run by the founder of Braintree, now a division of PayPal.

Partnering with this bioscience start-up is a strategic move by Cybin. Kernel is bringing the brain online via the blockchain. Therefore, it stands to be a vital tool in furthering Cybin’s agenda to create the optimum range of therapeutics tailored to specific mental health disorders.

Cybin’s first Kernel flow study is underway to understand how best to use this revolutionary device. This will help make breakthroughs in identifying how best to administer the neuro-regenerative properties of therapeutics in repairing and creating neural pathways.

Therapy training program

This approach to mental health therapy is much more than simply administering a drug. This is particularly true with psychedelics, where set and setting are paramount to success. Therapists are required before, during, and after treatment, which requires a much higher number of trained therapists than currently available.

Cybin plans to develop a consistent level of practical care. This begins with coherent therapy training to ensure enough therapists are available when Cybin’s proprietary drugs come to market.

It is also building a relationship with an extensive network of clinics in preparation for supervised in-clinic treatment sessions.

Cybin’s vision is to eliminate the stigma surrounding these treatments, train therapists consistently, and build the infrastructure to offer consumers a one-stop-shop to meet their psychedelic therapeutic needs.

Download the investor deck to learn how early investors could profit!

Quality team

Cybin has a quality team at the helm with a shared vision for success. Their backgrounds span working for some of the world’s top pharmaceutical companies, including Merck, Elan, GSK, Sanofi, Eli Lilly, and UCB.

CEO Doug Drysdale has worked in the pharmaceutical industry for over 30 years. He also has extensive M&A experience and several prior years at the CEO level. He’s helped grow both private and public start-ups and enjoys being involved in a high-growth environment.

The management team is driven by the bold approach Cybin is taking in tackling depression and addiction. Between them, they have raised over $4bn within the healthcare sector for both private and public companies.

The co-founders and management team owns over 25% of the company’s shares, which is reassuring from an investor perspective. With founder control comes a desire to succeed and the motivation to benefit all shareholders.

Undervalued

Cybin has a much smaller market cap than its billion-dollar competitors Compass Pathways and MindMed. With Cybin’s programs, IP, and phenomenal team, it’s undoubtedly undervalued compared to its peers.

The company has already successfully attracted significant funding from institutional investors in the blue-chip biotech sector. These are long-term holders with a belief in the company.

Therefore, Cybin is well-funded to progress its clinical trials, M&A, and IP strategies. To date, it has already raised over C$120M.

Cybin is publicly listed on NEO and more recently joined the NYSE American. This will significantly improve liquidity and open the investment opportunity to the broader retail market.

The de-scheduling of illegal hallucinogens is gradually taking place worldwide, ensuring some level of legal access is underway. There’s already a safely controlled framework operating in Oregon.

This is an exciting space to be invested in as the total addressable market is vast, translating to a money-spinning opportunity for early investors.

Cybin’s unique selling point is a faster, more efficient treatment. This will have widespread appeal as it will be easier to scale.


IMPORTANT NOTICE AND DISCLAIMER

PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cybin to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of two hundred fifty-six thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.

AUTHORS: VALUETHEMARKETS

valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.

The post This undervalued stock is developing biotechnology-enhanced therapeutics to treat mental health. appeared first on Value the Markets.

Read More

Trending